[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-mucormycosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-mucormycosis":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100619067","chest-ct-scan-in-pulmonary-mucormycosis-prognostic-value-100619067",false,"NCT07339800","Chest CT Scan in Pulmonary Mucormycosis: Prognostic Value","RadioMucor","Inclusion Criteria:\n\n* Patients aged 18 years or older\n* Treated at Strasbourg University Hospital between January 1, 2009, and June 3, 2025\n* With a diagnosis of probable or proven invasive pulmonary infection with Mucorales according to the 2020 EORTC\u002FMSGERC criteria\n* Having undergone at least one CT scan including the thoracic region\n\nExclusion Criteria:\n\n* No CT scan including the thoracic region\n* No diagnosis of probable or proven invasive pulmonary infection with Mucorales (EORTC\u002FMSGERC 2020 criteria)","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","OBSERVATIONAL","Invasive pulmonary fungal infections caused by Mucorales are rare but severe and rapidly progressive, affecting immunocompromised patients. The role of chest imaging in their diagnosis is well established in the 2020 EORTC\u002FMSGERC criteria, and its use is almost systematic. However, the progression of lung parenchymal involvement and any potential prognostic radiological patterns in the follow-up of these infections are less well understood. This research aims to identify imaging characteristics predictive of favorable or unfavorable outcomes in infected patients, in order to better tailor follow-up and therapeutic options.",[24],"Pulmonary Mucormycosis",[24,26],"Fungal infections","RECRUITING","2026-01-05",{"date":30,"type":31},"2026-01-14","ACTUAL",{"date":33,"type":31},"2025-09-18",{"date":35,"type":20},"2026-09-19",{"name":37,"class":38},"University Hospital, Strasbourg, France","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100574200","phase-4-antifungal-drugs-in-pulmonary-mucormycosis-100574200","NCT06756191","Antifungal Drugs in Pulmonary Mucormycosis","Evaluation on Efficacy and Safety of Liposomal Amphotericin B(AmBisome® ) Combination with Isavuconazole Versus AmBisome® Alone for Treatment of Patients with Pulmonary Mucormycosis","Inclusion Criteria\n\n* Patients aged 18 years or older diagnosed with pulmonary mucormycosis (PM).\n* Individuals with Probable or proved PM, as indicated by clinical and radiological findings.\n\nExclusion Criteria:\n\n* Patients with a history of pulmonary mucormycosis (PM) who have previously been treated with amphotericin B for a duration exceeding 5 days.\n* Patients who have documented allergies to azoles or amphotericin B regimens\n* Patients with serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, or bilirubin levels exceeding five times the upper limit of normal (ULN).\n* Patients with irreversible heart or liver failure, or those experiencing massive, fatal hemoptysis.\n* Patients who have experienced a myocardial infarction or cerebral infarction.\n* Patients currently receiving extracorporeal membrane oxygenation (ECMO) treatment.\n* Pregnant or breastfeeding individuals. 8.Patients with individual reasons that may prevent them from completing the treatment protocol.",{"count":48,"type":20},312,"INTERVENTIONAL",[51],"PHASE4","Pulmonary mucormycosis (PM) poses a substantial clinical challenge, particularly among immunocompromised patients. The aim of the study is to determine the effectiveness and safety of administering AmBisome at a dose of 5mg\u002Fkg\u002Fday combined with isavuconazole versus using AmBisome for the management of pulmonary mucormycosis",[24],[24,55,56],"Amphotericin B liposome","isavuconazole","NOT_YET_RECRUITING","2024-12-25",{"date":60,"type":31},"2025-01-01",{"date":62,"type":20},"2025-01-10",{"date":64,"type":20},"2026-12-31",{"name":66,"class":38},"Bin Cao"]